Logo of Robert Koch InstituteLogo of Robert Koch Institute
Publication Server of Robert Koch Instituteedoc
de|en
View Item 
  • edoc-Server Home
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • View Item
  • edoc-Server Home
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
All of edoc-ServerCommunity & CollectionTitleAuthorSubjectThis CollectionTitleAuthorSubject
PublishLoginRegisterHelp
StatisticsView Usage Statistics
All of edoc-ServerCommunity & CollectionTitleAuthorSubjectThis CollectionTitleAuthorSubject
PublishLoginRegisterHelp
StatisticsView Usage Statistics
View Item 
  • edoc-Server Home
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • View Item
  • edoc-Server Home
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • View Item
2010-03-15Zeitschriftenartikel DOI: 10.1086/650700
Interferon Beta Modulates Endothelial Damage in Patients with Cardiac Persistence of Human Parvovirus B19 Infection
Schmidt-Lucke, Caroline
Spillmann, Frank
Bock, Thomas
Kühl, Uwe
Linthout, Sophie van
Schultheiss, Heinz-Peter
Tschöpe, Carsten
Background: In a phase 1 study, we investigated whether interferon beta reduced endothelial damage in patients with cardiac persistence of human parvovirus B19 (B19V) infection. Methods and results: In vitro, B19V infected cultivated endothelial cells (ECs), which led to a reduction in their viability (Pp.007). Interferon beta suppressed B19V replication by 63% (Pp.008) in ECs and increased their viability (Pp.021). Circulating mature apoptotic ECs (CMAECs [CD45-CD146+ cells expressing von Willebrand factor and annexin V]) and circulating progenitor cells (CPCs [CD34+KDR+ cells]) were quantified by flow cytometry in 9 symptomatic patients with cardiac B19V infection before and after 6 months of interferon beta therapy (16 MU) and were compared to levels in 9 healthy control subjects. Endothelial dysfunction was measured using flow-mediated dilatation of the forearm. Patients with B19V persistence had significantly higher (Pp.004) levels of CMAECs than did control subjects, which normalized after treatment (mean standard deviation, 0.06%-0.08% vs 0.01%-0.006%; Pp.008). Similar improvement was shown for flow-mediated dilatation (Pp.04) in the treatment group only (Pp.017 for the comparison with untreated patients with B19V persistence [np5]). There were significantly higher numbers of CPCs in patients with B19V persistence before therapy (mean standard deviation, 0.04%-0.05% vs 0.01%-0.004%; Pp.02) than in control subjects, which normalized after treatment (Pp.03). Conclusion: Thus, we present (for the first time, to our knowledge) a modulation of virally induced chronic endothelial damage specifically, EC apoptosis and endothelial regeneration.
Files in this item
Thumbnail
28rQSi4QT4F8.pdf — Adobe PDF — 913.5 Kb
MD5: 1179378c38b57722b74fd8e4e459adae
Cite
BibTeX
EndNote
RIS
No license information
Details
Terms of Use Imprint Policy Data Privacy Statement Contact

The Robert Koch Institute is a Federal Institute

within the portfolio of the Federal Ministry of Health

© Robert Koch Institute

All rights reserved unless explicitly granted.

 
DOI
10.1086/650700
Permanent URL
https://doi.org/10.1086/650700
HTML
<a href="https://doi.org/10.1086/650700">https://doi.org/10.1086/650700</a>